Inovio Pharmaceuticals (INO) Free Cash Flow (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Free Cash Flow of -$21.6 million for Q1 2026, down 10.74% sequentially from -$19.5 million in Q4 2025, and up 19.83% YoY from -$18.0 million in Q1 2025.
Inovio Pharmaceuticals (INO) Free Cash Flow (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at -$21.6 million in Q1 2026.
- Quarterly Free Cash Flow rose 19.83% year-over-year to -$21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$83.6 million (up 18.3% YoY) and the FY2025 annual result came in at -$88.9 million, up 14.97% from the prior year.
- Free Cash Flow retreated to -$21.6 million in Q1 2026 per INO's latest filing, from -$19.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$19.5 million in Q4 2025 and troughed at -$67.6 million in Q3 2022.
- A 5-year average of -$32.7 million and a median of -$27.9 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 44.78% in 2022, then jumped 56.91% in 2023.
- Over 5 years, Free Cash Flow stood at -$35.6 million in 2022, then rose by 26.28% to -$26.3 million in 2023, then advanced by 25.16% to -$19.7 million in 2024, then advanced by 0.84% to -$19.5 million in 2025, then fell by 10.74% to -$21.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$21.6 million, -$19.5 million, and -$21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.05 Mn |
| Jun 30, 2026 | -18.05 Mn |
| Mar 31, 2026 | -21.59 Mn |
| Mar 31, 2026 | -21.59 Mn |
| Dec 31, 2025 | -19.50 Mn |
| Dec 31, 2025 | -19.50 Mn |
| Sep 30, 2025 | -21.67 Mn |
| Sep 30, 2025 | -21.67 Mn |
| Jun 30, 2025 | -20.82 Mn |
| Jun 30, 2025 | -20.82 Mn |
| Mar 31, 2025 | -26.93 Mn |
| Mar 31, 2025 | -26.93 Mn |
| Dec 31, 2024 | -19.66 Mn |
| Dec 31, 2024 | -19.66 Mn |
| Sep 30, 2024 | -27.93 Mn |
| Sep 30, 2024 | -27.93 Mn |
| Jun 30, 2024 | -27.77 Mn |
| Jun 30, 2024 | -27.77 Mn |
| Mar 31, 2024 | -29.20 Mn |
| Mar 31, 2024 | -29.20 Mn |